This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
CRISPR Therapeutics (CRSP) Q1 Earnings and Revenues Beat
by Zacks Equity Research
CRISPR Therapeutics (CRSP) provides updates for its gene therapy candidates.
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 59.88% and 165.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 0% and 8.79%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -550% and 72.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR's (CRSP) first-quarter earnings call, investors will likely focus on its pipeline, especially its lead candidate exa-cel, due to the absence of marketed drugs.
Vertex (VRTX) Q1 Earnings Top Estimates, Revenues Up Y/Y
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) first-quarter 2023 earnings and sales beat estimates. Management reiterates financial guidance for 2023.
Moderna (MRNA) to Report Q1 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Investors focus will likely be on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports first-quarter earnings.
CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.13, moving +0.99% from the previous trading session.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $51.08 in the latest trading session, marking a -1.79% move from the prior day.
Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate
by Zacks Equity Research
Dermata (DRMA) gains on positive FDA response for the further development of DMT310 for treating severe to moderate acne.
Axsome (AXSM) Focuses on Auvelity Launch to Fuel Its Growth
by Zacks Equity Research
Axsome's (AXSM) earnings benefit from the launch of Auvelity (AXS-05), meant for treating major depressive disorders.
GSK Gears Up to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Bexsero, Shingrix and Juluca to drive first-quarter sales.
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex's (VRTX) Q1 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and development updates of its non-CF pipeline.
VYNE Gains on Preclinical Data for IPF Candidate
by Zacks Equity Research
VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis.
Here's Why You Should Add Allogene (ALLO) Stock to Your Portfolio
by Zacks Equity Research
Allogene Therapeutics (ALLO), a top-ranked stock, is currently focused on developing allogenic CAR T therapies for treating cancer.
Madrigal (MDGL) Gains on NASH Treatment's Breakthrough Therapy Tag
by Zacks Equity Research
Madrigal Pharmaceuticals (MDGL) gains on receiving Breakthrough Therapy designation from the FDA for resmetirom.
Gamida Cell (GMDA) Surges on FDA Approval for Omisirge
by Zacks Equity Research
Gamida Cell's (GMDA) shares surge as it receives FDA approval for Omisirge, an allogeneic cell therapy for blood cancer patients.
Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia
by Zacks Equity Research
Humanigen's (HGEN) shares surge after presenting promising early results of its Precision Approach to Chronic Myelomonocytic Leukemia study of lenzilumab in chronic myelomonocytic leukemia.
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $50.31 in the latest trading session, marking a -0.49% move from the prior day.
Regulus (RGLS) Surges on Enrollment Completion for RGLS8429
by Zacks Equity Research
Regulus (RGLS) surges as it completes enrollment in the first cohort to evaluate RGLS8429 for kidney disease.
Is BioRad Laboratories (BIO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Bio-Rad Laboratories (BIO) and CRISPR Therapeutics AG (CRSP) have performed compared to their sector so far this year.
CRISPR Therapeutics AG (CRSP) Soars 16.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug
by Zacks Equity Research
Panbela (PBLA) surges as it enrolls the first patient in the mid-stage clinical study to evaluate CPP-1X-T (Eflornithine tablets) for treating recent-onset type 1 diabetes.
Creative Medical (CELZ) Up 86% on Upbeat Diabetes Study Data
by Zacks Equity Research
Creative Medical Technology (CELZ) reports positive one-year follow-up data from a study showing the efficacy of CELZ-001 in treating type II diabetes without any serious adverse effects.
Humacyte (HUMA) Completes Enrollment in HAV Technology Study
by Zacks Equity Research
Humacyte (HUMA) surges as it completes patient enrollment in a late-stage clinical study on the human acellular vessel product for vascular access in hemodialysis patients.